Research Seminars

About

Research Seminars gather a small number (20 to 100) of well-established and preferably young investigators to address scientific topics in depth and help break new ground. Research Seminars take place over two days in easy-to-reach European cities. They are scientific Seminars involving recently published work and research in progress. Participation is fully supported by the budget granted by the ERS.

Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD

Despite remarkable progresses in the definition of cellular, biochemical and molecular biology pathways in the pathogenesis of Severe Asthma, Chronic Obstructive Pulmonary Disorder (COPD) and Interstitial Lung Disorders (ILDs), there is still a substantial unmet need for new drugs able to control and/or change the natural history of these diseases. This Seminar intended to underline the key role of a side-to-side collaboration between clinicians, scientists, bioinformaticians and statisticians in the comprehension of pathological processes underlying different respiratory disorders. It provided a framework to improve the ability to identify potential pharmacological targets for the development of innovative drugs.

Download all media

Characterisation of clinical phenotypes is mandatory for the development of new drugs N. Roche (Paris, France)
Asthma and COPD: similarities and differences in pathogenesis A. Di Stefano (Veruno, Italy)
Bioinformatic tools for systems medicine in allergy M. Benson (Linköping, Sweden)
Human translational medicine – phenotyping is key R. Djukanovic (Southampton, United Kingdom)
Lipidomic phenotyping of severe asthma J. Brandsma (Southampton, United Kingdom)
New drugs for severe asthma – what should we target and how? K.F. Chung (London, United Kingdom)
Translational research approaches for finding new therapeutic targets involved in viral-induced asthma and COPD exacerbation L. Uller (Lund, Sweden)
Developing integrated handprints of severe asthma: the U-BIOPRED approach B. De Meulder (Lyon, France)
Human translational medicine in ILD: the promise of new drugs O. Eickelberg (Munich, Germany)
New Drugs for COPD: the current status I. Adcock (London, United Kingdom)
COPD – will new insights into molecular pathology define new therapies? C. Greene (Dublin, Ireland)
What are the knowledge gaps in COPD that prevent new drug development? G. Caramori (Ferrara, Italy)
Chaperonins in COPD F. Cappello (Palermo, Italy)